Journal of Current Glaucoma Practice

Register      Login

VOLUME 15 , ISSUE 2 ( May-August, 2021 ) > List of Articles

ORIGINAL RESEARCH

Effect of Topical Dexmedetomidine (0.0055%) on Intraocular Pressure in Healthy Eyes: A Randomized Controlled Trial

Henry Fakhoury, Youssef Abdelmassih, Sylvain el-Khoury, Mazen Amro, Karen Zaarour, Carole Cherfan, Karim Tomey, Ziad Khoueir

Keywords : Dexmedetomidine drops, Glaucoma, Intraocular pressure, Medication

Citation Information : Fakhoury H, Abdelmassih Y, el-Khoury S, Amro M, Zaarour K, Cherfan C, Tomey K, Khoueir Z. Effect of Topical Dexmedetomidine (0.0055%) on Intraocular Pressure in Healthy Eyes: A Randomized Controlled Trial. J Curr Glaucoma Pract 2021; 15 (2):58-63.

DOI: 10.5005/jp-journals-10078-1310

License: CC BY-NC 4.0

Published Online: 30-09-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim and objective: Evaluate the short-term safety and efficacy of dexmedetomidine (0.0055%) drops on intraocular pressure (IOP) in healthy eyes. Materials and methods: In this randomized controlled trial, patients with normal eye exams were randomly assigned to receive, in a randomly selected eye, one drop of either balanced salt solution (BSS) or dexmedetomidine (0.0055%). Goldmann applanation tonometry was performed at baseline and then 30 minutes, 4 hours, and 24 hours after drop instillation. Results: Forty-nine eyes of 49 normal volunteers were enrolled in the study, with 21 eyes (group I) receiving BSS and 28 (group II) dexmedetomidine. Both groups were comparable at baseline as far as age and IOP (p = 0.55 for both parameters). Intraocular pressure significantly decreased from baseline in group II at 30 minutes and 4 hours (p = 0.001 and 0.05, respectively). Maximum IOP decrease was obtained at 30 minutes after dexmedetomidine instillation, with a 9% decrease from baseline (mean decrease: 1.15 mm Hg). The percentage of IOP decrease was significantly higher in group II at 30 minutes compared with group I (9 vs 1.1%; p = 0.05). No side effects were recorded. Conclusion: In this pilot study, dexmedetomidine 0.0055% drops have shown good safety and efficacy in lowering IOP in normal healthy volunteers with no history of glaucoma. This medication has a short onset of action, with a 10% reduction of IOP occurring 30 minutes post-instillation. Trial registration number: NCT03690622.


PDF Share
  1. Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
  2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262–267. DOI: 10.1136/bjo.2005.081224.
  3. Tătaru CP, Purcărea VL. Antiglaucoma pharmacotherapy. J Med Life 2012;5(3):247–251.
  4. Arita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea 2012;31(11):1229–1234. DOI: 10.1097/ICO.0b013e31823f8e7d.
  5. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000;22(2):167–208. DOI: 10.1016/S0149-2918(00)88478-7.
  6. Bischoff P, Kochs E. Alpha 2-agonists in anesthesia and intensive medicine. Anasthesiologie Intensivmed Notfallmedizin Schmerzther AINS 1993;28(1):2–12. DOI: 10.1055/s-2007-998867.
  7. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma 1997;6(4):250–258. DOI: 10.1097/00061198-199708000- 00010.
  8. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol Chic Ill 1960 1995;113(12):1514–1517. DOI: 10.1001/archopht.1995.01100120044006.
  9. Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995;102(3):456–461. DOI: 10.1016/s0161-6420(95)31000-7.
  10. Kim NY, Yoo Y-C, Park H, et al. The effect of dexmedetomidine on intraocular pressure increase in patients during robot-assisted laparoscopic radical prostatectomy in the steep Trendelenburg position. J Endourol 2015;29(3):310–316. DOI: 10.1089/end.2014.0381.
  11. Zhou C, Zhu Y, Liu Z, et al. The effects of intravenous dexmedetomidine injections on IOP in general anesthesia intubation: a meta-analysis. Biomed Res Int 2017;2017:6186832. DOI: 10.1155/2017/6186832.
  12. McAuliffe-Curtin D, Buckley C. Review of alpha adrenoceptor function in the eye. Eye Lond Engl 1989;3(Pt 4):472–476. DOI: 10.1038/eye.1989.71.
  13. Vartiainen J, MacDonald E, Urtti A, et al. Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. Invest Ophthalmol Vis Sci 1992;33(6):2019–2023.
  14. Abdelhamid A, Mahmoud A, Abdelhaq M, et al. Dexmedetomidine as an additive to local anesthetics compared with intravenous dexmedetomidine in peribulbar block for cataract surgery. Saudi J Anaesth 2016;10(1):50–54. DOI: 10.4103/1658-354X.169475.
  15. Horn G, Compositions and methods for treatment of glaucoma. US8445526 B2, 2013. Available: http://www.google.com.pg/patents/US8445526.
  16. Effect Topical Dexmedetomidine on Intraocular Pressure - Full Text View - ClinicalTrials.gov. [cited 1 Oct 2018]. Available: https://clinicaltrials.gov/ct2/show/NCT03690622.
  17. Chow S, Shao J, Wang H. Sample size calculations in clinical research. 2nd ed., Chapman & Hall/CRC Biostatistics Series; 2008.
  18. Rasmussen CA, Kaufman PL, Kiland JA. Benzalkonium chloride and glaucoma. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 2014;30(2-3):163–169. DOI: 10.1089/jop.2013.0174.
  19. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007;18(2):134–139. DOI: 10.1097/ICU.0b013e328089f1c8.
  20. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag 2006;2(4):337–346. DOI: 10.2147/tcrm.2006.2.4.337.
  21. Heijl A, Leske MC, Hyman L, et al. Intraocular pressure reduction with a fixed treatment protocol in the early manifest glaucoma trial. Acta Ophthalmol (Copenh) 2011;89(8):749–754. DOI: 10.1111/j.1755-3768.2009.01852.x.
  22. Ang GS, Kersey JP, Shepstone L, et al. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol 2008;92(8):1129–1133. DOI: 10.1136/bjo.2007.135269.
  23. Parikh RS, Parikh SR, Navin S, et al. Practical approach to medical management of glaucoma. Indian J Ophthalmol 2008;56(3):223–230. DOI: 10.4103/0301-4738.40362.
  24. Sridharrao B, Badrinath SS. Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery. Br J Ophthalmol 1989;73(11):884–887. DOI: 10.1136/bjo.73. 11.884.
  25. Chevrier RL, Assalian A, Duperré J, et al. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. Ophthalmic Surg Lasers 1999;30(3):199–204. DOI: 10.3928/1542-8877-19990301-08.
  26. Barnes SD, Campagna JA, Dirks MS, et al. Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. Ophthalmology 1999;106(10):2033–2037. DOI: 10.1016/S0161-6420(99) 90420-7.
  27. Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev 2017;2:CD010746. DOI: 10.1002/14651858.CD010746.pub2.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.